Of note, OC2 mRNA expression is highest in the HER2 + subtype (Fig. 4J and Supplementary Fig. 4J) suggesting that OC2 might be active in a broader group of hormone receptor-negative aggressive BC tumors with poor prognosis. This evidence concerns the gene ONECUT2 and breast cancer.